Sažetak
Background: While individual cytokines have been implicated in the pathogenesis of acute myocardial infarction (AMI), the predictive utility of a comprehensive serum cytokine panel for post-infarction outcomes remains underexplored.
Methods: We conducted a prospective cohort study of 184 patients presenting with ST-segment elevation myocardial infarction (STEMI). Blood samples were collected within 24 hours of primary percutaneous coronary intervention (PCI). A panel of 11 cytokines (GDF-15, IL-1β, IL-6, IL-8, IL-10, IFN-γ, VEGF, G-CSF, GM-CSF, TGF-β, and hs-cTnT) was analyzed using multiplex bead-based immunoassay. The primary endpoint was the occurrence of Major Adverse Cardiac Events (MACE) at 12 months, defined as cardiovascular death, recurrent MI, or heart failure hospitalization.
Results: Elevated levels of IL-6, IL-8, GDF-15, and hs-cTnT were significantly associated with 12-month MACE. Multivariable logistic regression identified GDF-15 (OR 3.58, 95% CI 1.82–7.04, p<0.001) and hs-cTnT (OR 2.94, 95% CI 1.53–5.65, p=0.001) as independent predictors. A composite biomarker score demonstrated an AUC of 0.86 (95% CI 0.80–0.92) for predicting MACE.
Conclusion: A specific serum biomarker profile, particularly involving GDF-15 and hs-cTnT, independently predicts adverse outcomes post-MI. Routine biomarker profiling may enhance risk stratification beyond traditional clinical variables.
Ključne reči
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.